- $485.88m
- $260.49m
Neurogene jumps after FDA's breakthrough tag for neurological disorder therapy
Brief: Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Brief: Neurogene Announces Inducement Grant Under Nasdaq Listing Rule
Gene therapy developer Neurogene's Q3 net loss widens
Brief: Neurogene Q3 EPS USD -0.99
Brief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule
Brief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neurogene Q2 Net Income USD -22.016 Million
Brief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc expected to post a loss of $1.16 a share - Earnings Preview
Brief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene jumps as FDA approves rare gene therapy trial design
Brief: Neurogene Launches Registrational Trial Design for NGN-401 Gene Therapy in Rett Syndrome Study
Brief: Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav
Neurogene Inc reports results for the quarter ended March 31 - Earnings Summary
Gene therapy and vaccine makers fall after FDA names Vinay Prasad as top vaccine official
Neurogene Inc expected to post a loss of $1.06 a share - Earnings Preview
Brief: Neurogene Announces Upcoming Oral Presentation On Monitoring And Treatment To Reverse Rare Complication Of High Dose Gene Therapy